THERAPEUTIC HOTLINE: Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report

摘要: Pyoderma gangrenosum (PG) is a rare, noninfectious, neutrophilic dermatosis of unknown origin that associated with systemic diseases in 50% cases. The authors present case 54-year-old man patient refractory to conventional treatment PG ulcerative colitis and psoriasis, which showed successful response infliximab, chimeric monoclonal antibody inhibits tumor necrosis factor alpha (TNF-α). This report shows the frequent difficulty therapeutic approach PG, especially if underlying disease, necessity apply new agents, such as novel application TNF-α inhibitors, relationship recent pathogenic knowledge.